文献速递肝胆胰外科

SynchroSeal在机器人肝实质离断中的安全性与有效性

Robotic liver parenchymal transection using the SynchroSeal.
PubMed 文献 · Surg Endosc · 2024-07-08

本研究为前瞻性收集数据的回顾性分析,比较SynchroSeal与Vessel Sealer Extend在机器人肝切除中的表现。倾向评分匹配后,SynchroSeal组术中出血量显著更少(48 mL vs 95 mL,p=0.032),其他围术期结局相似,提示其安全有效。

要点

  • SynchroSeal组转换率0.6%,中位出血量40 mL,中位住院3天。
  • 匹配比较中SynchroSeal出血量显著少于Vessel Sealer(p=0.032)。
  • 两组总体并发症(19.4%)与严重并发症(11.0%)相近。

核心结论

  • SynchroSeal是机器人肝实质离断安全有效的器械。

研究设计与样本

  • 研究为前瞻性收集数据的回顾性分析,纳入两家高容量中心行机器人肝切除的患者。
  • SynchroSeal组155例,Vessel Sealer组145例,经倾向评分匹配后各94例比较。

主要发现

  • SynchroSeal组转换率0.6%(n=1),术中出血量中位40 mL(IQR 10-100),住院中位3天(IQR 2-4)。
  • SynchroSeal组总体并发症19.4%,严重并发症11.0%。
  • 匹配比较中SynchroSeal组出血量48 mL(IQR 10-143)少于Vessel Sealer组95 mL(IQR 30-200),p=0.032。
  • 其他围术期结局两组相似。

临床怎么用

  • 在机器人肝切除中可选用SynchroSeal进行肝实质离断,可能有助于减少术中出血。

局限性

  • 研究为回顾性分析,非随机对照,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is much heterogeneity in the instrumentation used for parenchymal transection in minimally invasive liver surgery. Instruments specifically designed for robotic parenchymal transection of the liver are lacking. We aim to gain insight into the safety and effectiveness of the SynchroSeal (Intuitive Surgical, Inc., Sunnyvale, CA), a novel bipolar electrosurgical device, in the context of liver surgery. METHODS: The present study is a post-hoc analysis of prospectively collected data from patients undergoing robotic liver resection (RLR) using the SynchroSeal in two high-volume centres. The results of the SynchroSeal were compared with that of the previous generation bipolar-sealer; Vessel Sealer Extend (Intuitive Surgical, Inc., Sunnyvale, CA) using propensity score matching, after excluding the first 25 Vessel Sealer procedures per center. RESULTS: During the study period (February 2020-March 2023), 155 RLRs meeting the eligibility criteria were performed with the SynchroSeal (after implementation in June 2021) and 145 RLRs with the Vessel Sealer. Excellent outcomes were achieved when performing parenchymal transection with the SynchroSeal; low conversion rate (n = 1, 0.6%), small amounts of intraoperative blood loss (median 40 mL [IQR 10-100]), short hospital stays (median 3 days [IQR 2-4]), and adequate overall morbidity (19.4%) as well as severe morbidity (11.0%). In a matched comparison (n = 94 vs n = 94), the SynchroSeal was associated with less intraoperative blood loss (48 mL [IQR 10-143] vs 95 mL [IQR 30-200], p = 0.032) compared to the Vessel Sealer. Other perioperative outcomes were similar between the devices. CONCLUSION: The SynchroSeal is a safe and effective device for robotic liver parenchymal transection.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Pilz da Cunha G, De Meyere C, D'Hondt M, et al. Robotic liver parenchymal transection using the SynchroSeal. Surg Endosc. 2024. PMID: 38977499. doi:10.1007/s00464-024-11005-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。